Purified extract (ATC2) isolated from
A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.
1. A purified extract with the secondary fractionation (ATC2) from the extract of Pseudolysimachion rotundum var subintegrum , which contains 30-60% (w/w) verproside, 0.5-10% (w/w) veratric acid, 2-20% (w/w) catalposide, 1-10% (w/w) picroside II, 1-10% (w/w) isovanilloyl catalpol and 2-20% (w/w) 6-O-veratroyl catalpol based on the weight of total extract (100%) of Pseudolysimachion rotundum var subintegrum.
2. A purified extract with the secondary fractionation (ATC2) from the extract of Pseudolysimachion rotundum var subintegrum , which contains 36.5-91% (w/w) catalpol derivatives selected from the group consisting of verproside, veratric acid, catalposide, picroside II, isovanilloyl catalpol and 6-O-veratroyl catalpol in total extract (100%) of Pseudolysimachion rotundum var subintegrum and which shows relative mixed ratio (w/w) between weight of each catalpol derivative, of 13.0-16.0 (w/w) verproside, 2.20-2.50 (w/w) catalposide, 1 (w/w) picroside II, 1.10-1.40 (w/w) isovanilloyl catalpol and 2.00-2.20 (w/w) 6-O-veratroyl catalpol.
3. A pharmaceutical composition comprising the purified extract with the secondary fractionation (ATC2) as set forth in claim 1 ; isolated from Pseudolysimachion rotundum var subintegrum as an active ingredient and a pharmaceutically acceptable carrier or excipient.
4. A pharmaceutical composition comprising the purified extract with the secondary fractionation (ATC2) as set forth in claim 2 ; isolated from Pseudolysimachion rotundum var subintegrum as an active ingredient and a pharmaceutically acceptable carrier or excipient.
5. A health functional food comprising the purified extract with the secondary fractionation (ATC2) as set forth in claim 1 ; isolated from Pseudolysimachion rotundum var subintegrum.
6. A health functional food comprising the purified extract with the secondary fractionation (ATC2) as set forth in claim 2 ; isolated from Pseudolysimachion rotundum var subintegrum.